~ Buy the SMOFLIPID 20% (fish oil; medium chain triglycerides; olive oil; soybean oil) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SMOFLIPID 20%

All Clinical Trials for SMOFLIPID 20%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00451646 ↗	Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition	Completed	Fresenius Kabi	Phase 3	2007-10-01	The aim of this study is to evaluate the safety and tolerance of SMOFlipid 20% in comparison to a standard lipid emulsion Intralipid 20% in patients requiring long-term parenteral nutrition. The safety and tolerance will be evaluated by biochemistry, hematology and coagulation variables, vital signs and adverse events. Further objectives to evaluate are the influence of SMOFlipid 20% on inflammation processes, the efficacy of anti-oxidative properties of vitamin E supplemented to SMOFlipid 20%, and the fatty acid pattern in red blood cells and serum.
NCT00793195 ↗	Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?	Unknown status	Fresenius Kabi	Phase 2	2009-01-01	The aim of this study is to determine the feasibility of conducting a trial to examine the efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention of progression of PNALD in infants with Intestinal Failure/Short Bowel Syndrome (SBS) and early liver dysfunction.
NCT00793195 ↗	Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?	Unknown status	The Hospital for Sick Children	Phase 2	2009-01-01	The aim of this study is to determine the feasibility of conducting a trial to examine the efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention of progression of PNALD in infants with Intestinal Failure/Short Bowel Syndrome (SBS) and early liver dysfunction.
NCT00885781 ↗	Efficacy and Safety Comparison Between SMOFlipid and Lipovenoes MCT	Completed	National Taiwan University Hospital	Phase 4	2008-11-01	Comparison of efficacy and safety of two lipid emulsion products will be performed on gastrectomy patients postsurgically.

Clinical Trial Conditions for SMOFLIPID 20%

Condition Name

Condition Name for SMOFLIPID 20%
Intervention	Trials
Cholestasis	3
Short Bowel Syndrome	2
Parenteral Nutrition	2
Growth Failure	1

Condition MeSH

Condition MeSH for SMOFLIPID 20%
Intervention	Trials
Cholestasis	4
Malnutrition	2
Premature Birth	2
Short Bowel Syndrome	2

Clinical Trial Locations for SMOFLIPID 20%

Trials by Country

Trials by Country for SMOFLIPID 20%
Location	Trials
United States	17
Australia	2
Egypt	2
France	2
Canada	2

Trials by US State

Trials by US State for SMOFLIPID 20%
Location	Trials
Florida	2
Pennsylvania	2
Texas	2
Indiana	1
Minnesota	1

Clinical Trial Progress for SMOFLIPID 20%

Clinical Trial Phase

Clinical Trial Phase for SMOFLIPID 20%
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	6
Phase 2	1

Clinical Trial Status

Clinical Trial Status for SMOFLIPID 20%
Clinical Trial Phase	Trials
Completed	8
Recruiting	4
Terminated	2

Clinical Trial Sponsors for SMOFLIPID 20%

Sponsor Name

Sponsor Name for SMOFLIPID 20%
Sponsor	Trials
Fresenius Kabi	6
Assiut University	2
University of Florida	2

Sponsor Type

Sponsor Type for SMOFLIPID 20%
Sponsor	Trials
Other	18
Industry	6